Lancet Oncology最新文献

筛选
英文 中文
Leaked documents suggest Philip Morris International's link to research activities. 泄露的文件显示菲利普莫里斯国际公司与研究活动有关联。
IF 41.6 1区 医学
Lancet Oncology Pub Date : 2024-08-01 Epub Date: 2024-07-14 DOI: 10.1016/S1470-2045(24)00393-0
Talha Burki
{"title":"Leaked documents suggest Philip Morris International's link to research activities.","authors":"Talha Burki","doi":"10.1016/S1470-2045(24)00393-0","DOIUrl":"10.1016/S1470-2045(24)00393-0","url":null,"abstract":"","PeriodicalId":17942,"journal":{"name":"Lancet Oncology","volume":" ","pages":"964"},"PeriodicalIF":41.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141620355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. 针对复发和难治性多发性骨髓瘤临床实践中嵌合抗原受体 T 细胞疗法的管理和反应评估的共识指南和建议:国际骨髓瘤工作组免疫疗法委员会的报告。
IF 41.6 1区 医学
Lancet Oncology Pub Date : 2024-08-01 Epub Date: 2024-05-28 DOI: 10.1016/S1470-2045(24)00094-9
Yi Lin, Lugui Qiu, Saad Usmani, Chng Wee Joo, Luciano Costa, Benjamin Derman, Juan Du, Hermann Einsele, Carlos Fernandez de Larrea, Roman Hajek, P Joy Ho, Efstathios Kastritis, Joaquin Martinez-Lopez, Maria-Victoria Mateos, Joseph Mikhael, Philippe Moreau, Chandramouli Nagarajan, Ajay Nooka, Michael O'Dwyer, Fredrik Schjesvold, Surbhi Sidana, Niels Wcj van de Donk, Katja Weisel, Sonja Zweegman, Noopur Raje, Paula Rodriguez Otero, Larry D Anderson, Shaji Kumar, Tom Martin
{"title":"Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee.","authors":"Yi Lin, Lugui Qiu, Saad Usmani, Chng Wee Joo, Luciano Costa, Benjamin Derman, Juan Du, Hermann Einsele, Carlos Fernandez de Larrea, Roman Hajek, P Joy Ho, Efstathios Kastritis, Joaquin Martinez-Lopez, Maria-Victoria Mateos, Joseph Mikhael, Philippe Moreau, Chandramouli Nagarajan, Ajay Nooka, Michael O'Dwyer, Fredrik Schjesvold, Surbhi Sidana, Niels Wcj van de Donk, Katja Weisel, Sonja Zweegman, Noopur Raje, Paula Rodriguez Otero, Larry D Anderson, Shaji Kumar, Tom Martin","doi":"10.1016/S1470-2045(24)00094-9","DOIUrl":"10.1016/S1470-2045(24)00094-9","url":null,"abstract":"<p><p>Chimeric antigen receptor (CAR) T-cell therapy has shown promise in patients with late-line refractory multiple myeloma, with response rates ranging from 73 to 98%. To date, three products have been approved: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), which are approved by the US Food and Drug Administration, the European Medicines Agency, Health Canada (ide-cel only), and Brazil ANVISA (cilta-cel only); and equecabtagene autoleucel (eque-cel), which was approved by the Chinese National Medical Products Administration. CAR T-cell therapy is different from previous anti-myeloma therapeutics with unique toxic effects that require distinct mitigation strategies. Thus, a panel of experts from the International Myeloma Working Group was assembled to provide guidance for clinical use of CAR T-cell therapy in myeloma. This consensus opinion is from experts in the field of haematopoietic cell transplantation, cell therapy, and multiple myeloma therapeutics.</p>","PeriodicalId":17942,"journal":{"name":"Lancet Oncology","volume":" ","pages":"e374-e387"},"PeriodicalIF":41.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141183294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Closing the research gaps in obstetric health for survivors of cancer. 缩小癌症幸存者产科保健方面的研究差距。
IF 41.6 1区 医学
Lancet Oncology Pub Date : 2024-08-01 Epub Date: 2024-06-26 DOI: 10.1016/S1470-2045(24)00321-8
Ranjeet Bajpai, Jyoti Bajpai
{"title":"Closing the research gaps in obstetric health for survivors of cancer.","authors":"Ranjeet Bajpai, Jyoti Bajpai","doi":"10.1016/S1470-2045(24)00321-8","DOIUrl":"10.1016/S1470-2045(24)00321-8","url":null,"abstract":"","PeriodicalId":17942,"journal":{"name":"Lancet Oncology","volume":" ","pages":"953-955"},"PeriodicalIF":41.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141469141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ImmunoPET in high-grade neuroendocrine tumours. 高分化神经内分泌肿瘤的免疫PET。
IF 41.6 1区 医学
Lancet Oncology Pub Date : 2024-08-01 Epub Date: 2024-06-28 DOI: 10.1016/S1470-2045(24)00314-0
Francesco Giammarile, Roberto C Delgado Bolton, Fuad Novruzov, Diana Paez
{"title":"ImmunoPET in high-grade neuroendocrine tumours.","authors":"Francesco Giammarile, Roberto C Delgado Bolton, Fuad Novruzov, Diana Paez","doi":"10.1016/S1470-2045(24)00314-0","DOIUrl":"10.1016/S1470-2045(24)00314-0","url":null,"abstract":"","PeriodicalId":17942,"journal":{"name":"Lancet Oncology","volume":" ","pages":"949-950"},"PeriodicalIF":41.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141476908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Challenges and prospects for cancer treatment in prison settings. 监狱环境中癌症治疗的挑战和前景。
IF 41.6 1区 医学
Lancet Oncology Pub Date : 2024-08-01 DOI: 10.1016/S1470-2045(24)00272-9
Hujian Hong, Yanli Qu
{"title":"Challenges and prospects for cancer treatment in prison settings.","authors":"Hujian Hong, Yanli Qu","doi":"10.1016/S1470-2045(24)00272-9","DOIUrl":"https://doi.org/10.1016/S1470-2045(24)00272-9","url":null,"abstract":"","PeriodicalId":17942,"journal":{"name":"Lancet Oncology","volume":"25 8","pages":"e332"},"PeriodicalIF":41.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141875167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Challenges and prospects for cancer treatment in prison settings. 监狱环境中癌症治疗的挑战和前景。
IF 41.6 1区 医学
Lancet Oncology Pub Date : 2024-08-01 DOI: 10.1016/S1470-2045(24)00328-0
Feng Zhang
{"title":"Challenges and prospects for cancer treatment in prison settings.","authors":"Feng Zhang","doi":"10.1016/S1470-2045(24)00328-0","DOIUrl":"https://doi.org/10.1016/S1470-2045(24)00328-0","url":null,"abstract":"","PeriodicalId":17942,"journal":{"name":"Lancet Oncology","volume":"25 8","pages":"e333"},"PeriodicalIF":41.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141875168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study. 局部晚期微卫星不稳定性高或错配修复缺陷结直肠癌新辅助卡瑞珠单抗加阿帕替尼(NEOCAP):一项单臂、开放标签、2 期研究。
IF 41.6 1区 医学
Lancet Oncology Pub Date : 2024-07-01 Epub Date: 2024-06-06 DOI: 10.1016/S1470-2045(24)00203-1
Jie-Hai Yu, Bin-Yi Xiao, Dan-Dan Li, Wu Jiang, Ya Ding, Xiao-Jun Wu, Rong-Xin Zhang, Jun-Zhong Lin, Wei Wang, Kai Han, Ling-Heng Kong, Xin-Ke Zhang, Bi-Yun Chen, Wei-Jian Mei, Zhi-Zhong Pan, Jing-Hua Tang, Xiao-Shi Zhang, Pei-Rong Ding
{"title":"Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study.","authors":"Jie-Hai Yu, Bin-Yi Xiao, Dan-Dan Li, Wu Jiang, Ya Ding, Xiao-Jun Wu, Rong-Xin Zhang, Jun-Zhong Lin, Wei Wang, Kai Han, Ling-Heng Kong, Xin-Ke Zhang, Bi-Yun Chen, Wei-Jian Mei, Zhi-Zhong Pan, Jing-Hua Tang, Xiao-Shi Zhang, Pei-Rong Ding","doi":"10.1016/S1470-2045(24)00203-1","DOIUrl":"10.1016/S1470-2045(24)00203-1","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;PD-1 blockade is highly efficacious for mismatch repair-deficient colorectal cancer in both metastatic and neoadjuvant settings. We aimed to explore the activity and safety of neoadjuvant therapy with PD-1 blockade plus an angiogenesis inhibitor and the feasibility of organ preservation in patients with locally advanced mismatch repair-deficient colorectal cancer.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We initiated a single-arm, open-label, phase 2 trial (NEOCAP) at Sun Yat-sen University Cancer Center and the Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China. Patients aged 18-75 years with untreated mismatch repair-deficient or microsatellite instability-high or POLE/POLD1-mutated locally advanced colorectal cancer (cT3 or N+ for rectal cancer, and T3 with invasion ≥5mm or T4, with or without N+ for colon cancer) and an Eastern Cooperative Oncology Group performance score of 0-1 were enrolled and given 200 mg camrelizumab intravenously on day 1 and 250 mg apatinib orally from day 1-14, every 3 weeks for 3 months followed by surgery or 6 months if patients did not have surgery. Patients who had a clinical complete response did not undergo surgery and proceeded with a watch-and-wait approach. The primary endpoint was the proportion of patients with a pathological or clinical complete response. Eligible enrolled patients who received at least one cycle of neoadjuvant treatment and had at least one tumour response assessment following the baseline assessment were included in the activity analysis, and patients who received at least one dose of study drug were included in the safety analysis. The study is registered with ClinicalTrials.gov (NCT04715633) and is ongoing.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;Between Sept 29, 2020, and Dec 15, 2022, 53 patients were enrolled; one patient was excluded from the activity analysis because they were found to be mismatch repair-proficient and microsatellite-stable. 23 (44%) patients were female and 29 (56%) were male. The median follow-up was 16·4 (IQR 10·5-23·5) months. 28 (54%; 95% CI 35-68) patients had a clinical complete response and 24 of these patients were managed with a watch-and-wait approach, including 20 patients with colon cancer and multiple primary colorectal cancer. 23 (44%) of 52 patients underwent surgery for the primary tumour, and 14 (61%; 95% CI 39-80) had a pathological complete response. 38 (73%; 95% CI 59-84) of 52 patients had a complete response. Grade 3-5 adverse events occurred in 20 (38%) of 53 patients; the most common were increased aminotransferase (six [11%]), bowel obstruction (four [8%]), and hypertension (four [8%]). Drug-related serious adverse events occurred in six (11%) of 53 patients. One patient died from treatment-related immune-related hepatitis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Interpretation: &lt;/strong&gt;Neoadjuvant camrelizumab plus apatinib show promising antitumour activity in patients with locally advanced mismatch repair-deficient or microsa","PeriodicalId":17942,"journal":{"name":"Lancet Oncology","volume":" ","pages":"843-852"},"PeriodicalIF":41.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141296364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tobacco and e-cigarette use in young people: an ongoing challenge. 青少年使用烟草和电子烟:一项持续的挑战。
IF 41.6 1区 医学
Lancet Oncology Pub Date : 2024-07-01 Epub Date: 2024-05-31 DOI: 10.1016/S1470-2045(24)00323-1
Talha Burki
{"title":"Tobacco and e-cigarette use in young people: an ongoing challenge.","authors":"Talha Burki","doi":"10.1016/S1470-2045(24)00323-1","DOIUrl":"10.1016/S1470-2045(24)00323-1","url":null,"abstract":"","PeriodicalId":17942,"journal":{"name":"Lancet Oncology","volume":" ","pages":"835"},"PeriodicalIF":41.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141236251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to Lancet Oncol 2024; 25: e205-16. Lancet Oncol 2024; 25: e205-16 更正。
IF 41.6 1区 医学
Lancet Oncology Pub Date : 2024-07-01 DOI: 10.1016/S1470-2045(24)00288-2
{"title":"Correction to Lancet Oncol 2024; 25: e205-16.","authors":"","doi":"10.1016/S1470-2045(24)00288-2","DOIUrl":"https://doi.org/10.1016/S1470-2045(24)00288-2","url":null,"abstract":"","PeriodicalId":17942,"journal":{"name":"Lancet Oncology","volume":"25 7","pages":"e284"},"PeriodicalIF":41.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141469154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overcoming barriers to early breast cancer presentation in Nigeria. 克服尼日利亚早期乳腺癌发病的障碍。
IF 41.6 1区 医学
Lancet Oncology Pub Date : 2024-07-01 DOI: 10.1016/S1470-2045(24)00319-X
Mercy Ofuya
{"title":"Overcoming barriers to early breast cancer presentation in Nigeria.","authors":"Mercy Ofuya","doi":"10.1016/S1470-2045(24)00319-X","DOIUrl":"10.1016/S1470-2045(24)00319-X","url":null,"abstract":"","PeriodicalId":17942,"journal":{"name":"Lancet Oncology","volume":"25 7","pages":"840"},"PeriodicalIF":41.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141469160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信